

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7	May 07	DGENE Reload
NEWS 8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS 9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI
NEWS 10	Aug 23	In-process records and more frequent updates now in MEDLINE
NEWS 11	Aug 23	PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12	Aug 23	Adis Newsletters (ADISNEWS) now available on STN
NEWS 13	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS EXPRESS	August 15	CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:47:03 ON 18 SEP 2001

=> file medline, uspat, dgene, wpids, embase, hcaplus, frosti, japio

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FILE 'MEDLINE' ENTERED 11:47:51 ON 18 SEP 2001

FILE 'USPATFULL' ENTERED AT 11:47:51 ON 18 SEP 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 11:47:51 ON 18 SEP 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'WPIDS' ENTERED AT 11:47:51 ON 18 SEP 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 11:47:51 ON 18 SEP 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 11:47:51 ON 18 SEP 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'FROSTI' ENTERED AT 11:47:51 ON 18 SEP 2001
COPYRIGHT (C) 2001 Leatherhead Food Research Association

FILE 'JAPIO' ENTERED AT 11:47:51 ON 18 SEP 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

=> s efp or elongation factor p

L1 704 EFP OR ELONGATION FACTOR P

=> s compound () increase () efp activity

L2 0 COMPOUND (W) INCREASE (W) EFP ACTIVITY

=> s l1 and compound

L3 92 L1 AND COMPOUND

=> s l3 and increase activity

L4 0 L3 AND INCREASE ACTIVITY

=> s tryptophan and l3

L5 7 TRYPTOPHAN AND L3

=> s l5 and increas fluorescence

L6 0 L5 AND INCREAS FLUORESCENCE

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 7 USPATFULL

TI Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same

AB Recombinant nucleic acids which encode aminoacyl-trRNA sythetases of enterococcal origin or portions of such enzymes, have been isolated. These nucleic acids can be used to make expression constructs and transformed host cells for the production of enterococcal aminoacyl-trRNA

synthetases. They can also be used in the further isolation of nucleic acids related by DNA sequence similarities, which also encode

enterococcal aminoacyl-tRNA synthetases, or portions thereof. A further embodiment of the invention is antisense nucleic acid which can hybridize to the nucleic acid which encodes the aminoacyl-tRNA synthetase of enterococci. The invention also relates to tRNA synthetases such as isolated and/or recombinant enterococcal aminoacyl-tRNA synthetases. Antibodies which bind to these enzymes can be made and can be used in the purification and study of the enzymes. Tester strains, which are cells engineered to rely on the function of the tRNA synthetase encoded by an introduced cloned gene, can be used

to

test the effectiveness of drug candidates in the inhibition of the essential tRNA synthetase enzyme encoded by an introduced cloned gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:59662 USPATFULL
TITLE: Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same
INVENTOR(S): Tao, Jianshi, North Andover, MA, United States
Sassanfar, Mandana, Dedham, MA, United States
Gallant, Paul L., Dedham, MA, United States
Shen, Xiaoyu, Boston, MA, United States
Avruch, Anthony S., Watertown, MA, United States
Yu, Russell V., Munster, IN, United States
Nair, Shamila, Paris, France(4)
PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221640	B1	20010424
APPLICATION INFO.:	US 1997-855910		19970514 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hobbs, Lisa J.		
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds, P.C.		
NUMBER OF CLAIMS:	110		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	4482		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 7 USPATFULL

TI Interferon stimulating protein and uses thereof

AB This invention relates to the use of the baculovirus glycoprotein, Interferon Stimulating Protein (ISP) (also known as gp67, gp64 **EGF**, or gp64), or the gene sequence encoding ISP, to stimulate production of interferon, such as for immunotherapy, anti-viral, anti-cancer, anti-bacterial, or anti-parasitic therapy. This invention also relates to novel mutant forms of ISP that show enhanced biological (i.e., anti-viral) activity, increased stability, higher yield or better solubility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:163661 USPATFULL
TITLE: Interferon stimulating protein and uses thereof
INVENTOR(S): Hilbert, David M., Bethesda, MD, United States
Bednarik, Daniel P., Columbia, MD, United States
Nardelli, Bernadetta, Gaithersburg, MD, United States
Murphy, Marianne, Richmond, United Kingdom
Parmelee, David, Rockville, MD, United States
Gronowski, Ann, Ballwin, MO, United States
Schreiber, Robert, St. Louis, MO, United States
PATENT ASSIGNEE(S): Humn Genome Sciences, Inc., Rockville, MD, United

States (U.S. corporation)
Washington University, St. Louis, MO, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6001806		19991214
APPLICATION INFO.:	US 1998-105039		19980626 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51053	19970627 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	MacMillan, Keith D.	
ASSISTANT EXAMINER:	Wessendorf, T. D.	
LEGAL REPRESENTATIVE:	Hoover, Kenley K.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 15 Drawing Page(s)	
LINE COUNT:	3165	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 7 USPATFULL

TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:19275 USPATFULL
TITLE: Tumor necrosis factor receptor-associated factors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genetech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869612		19990209
APPLICATION INFO.:	US 1996-744139		19961105 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-250858, filed on 27 May 1994, now patented, Pat. No. US 5708142		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ulm, John		
LEGAL REPRESENTATIVE:	Dreger, Ginger R.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	3799		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 7 USPATFULL

TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAFs. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2) and CD40, and are involved in the mediation of TNF and CD40 ligand biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:42239 USPATFULL
TITLE: Tumor necrosis factor receptor-associated factors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5741667		19980421
APPLICATION INFO.:	US 1995-446915		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-331394, filed on 28 Oct 1994, now patented, Pat. No. US 5670319		

which

is a continuation-in-part of Ser. No. US 1994-250858, filed on 27 May 1994

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Dreger, Ginger R.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 4348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 7 USPATFULL

TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities,

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:4740 USPATFULL
TITLE: Tumor necrosis factor receptor-associated factors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5708142		19980113
APPLICATION INFO.:	US 1994-250858		19940527 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ulm, John		
LEGAL REPRESENTATIVE:	Dreger, Ginger R.		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	3737		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 7 USPATFULL

TI Assay for tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological

activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:86433 USPATFULL

TITLE: Assay for tumor necrosis factor receptor-associated factors

INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5670319		19970923
APPLICATION INFO.:	US 1994-331394		19941028 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-250858, filed on 27 May 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ulm, John		
LEGAL REPRESENTATIVE:	Dreger, Ginger R.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	3908		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 7 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Identifying a **compound** which modulates the activity of prokaryotic **elongation factor p (efp)**) for screening for compounds which can be used as antibiotics comprises contacting **efp** with a **compound** and determining if **efp** activity is modified.

AN 2000-524303 [47] WPIDS

AB WO 200045177 A UPAB: 20000925

NOVELTY - A method (M1) for identifying a **compound** which modulates the activity of **efp** comprises contacting **efp** with a **compound** and determining whether the **compound** modifies activity of **efp**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method (M2) for identifying a **compound** which modulates **efp** activity comprising:

(a) contacting a cell containing **efp** with a **compound** identified by M1; and
(b) determining whether the **compound** inhibits cell growth;

(2) a method (M3) for identifying a **compound** which modulates **efp** activity comprising:

(a) contacting a composition comprising **efp**, N-formylmethionyl-tRNA (fMet-tRNA), 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3 with a **compound**; and

(b) determining whether the **compound** allows fMet-tRNA to bind to a complex formed through the interaction of **efp**, 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3;

(3) a method (M4) for identifying a **compound** which modulates **efp** activity comprising:

(a) contacting **efp** with prokaryotic 30S subunit or 70S ribosome to form a composition;

(b) contacting the composition with a **compound**; and

(c) determining whether the **compound** binds to **efp** in association with the 30S subunit or 70S ribosome or interferes with

the binding of **efp** and the 30S subunit or 70S ribosome;

(4) a method (M5) for identifying a **compound** which modulates **efp** activity comprising:

(a) contacting **efp** with a composition comprising either 50S subunit or 70S ribosome, a tRNA fragment comprising CACCA-radiolabeled amino acid and a peptide bond donor to form a second composition;

(b) contacting the second composition with the **compound**; and

(c) determining whether the **compound** inhibits the first peptide bond reaction;

(5) a method (M6) for identifying a **compound** which modulates **efp** activity comprising:

(a) contacting a cell or composition containing **efp** with a detectably labelled oxazolidinone **compound** known to bind **efp**;

(b) contacting the composition or cell with an unlabelled **compound**; and

(c) determining whether the unlabelled **compound** displaces the labelled oxazolidinone **compound** from the complex;

(6) a method (M7) for identifying a **compound** which modulates **efp** but not eukaryotic eIF5A activity comprising:

(a) determining whether the **compound** modulates the activity of prokaryotic **efp** by M1 - M7;

(b) contacting eIF5A with a composition comprising methionyl-tRNA (Met-tRNA), 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C, eIF-4D and a peptide bond donor to form a second composition;

(c) contacting the second composition with a **compound**; and

(d) determining whether the **compound** inhibits the first peptide bond reaction of a complex formed through the interaction of eIF5A, Met-tRNA, 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C and eIF-4D; and

(7) modulating the activity of prokaryotic **efp**, the 30S subunit, 50S subunit, 70S ribosome or L16 protein comprising contacting the **efp** or cell or cell preparation containing the **efp**, the 30S subunit, 50S subunit, 70S ribosome or L16 protein with an oxazolidinone **compound**.

USE - To screen for compounds which modulate ribosome mediated peptide bond formation. These screening assays can be used to discover new and useful antibiotics.

ADVANTAGE - This screening method is more rapid and direct than currently available methods.

Dwg.0/0

ACCESSION NUMBER: 2000-524303 [47] WPIDS

DOC. NO. NON-CPI: N2000-387540

DOC. NO. CPI: C2000-155724

TITLE: Identifying a **compound** which modulates the activity of prokaryotic **elongation**

factor p (efp) for screening

for compounds which can be used as antibiotics comprises contacting **efp** with a **compound** and determining if **efp** activity is modified.

DERWENT CLASS: B04 D16 S03

INVENTOR(S): MAROTTI, K R; POORMAN, R A; SHINABARGER, D L; WELLS, P A

PATENT ASSIGNEE(S): (PHAA) PHARMACIA & UPJOHN

COUNTRY COUNT: 86

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----------	------	------	------	----	----

WO	2000045177	A1	20000803	(200047)*	EN 52
----	------------	----	----------	-----------	-------

RW:	AT	BE	CH	CY	DE	DK	EA	ES	FI	FR	GB	GH	GM	GR	IE	IT	KE	LS	LU	MC	MW	NL
	OA	PT	SD	SE	SL	SZ	UG	ZW														

W:	AE	AL	AM	AT	AU	AZ	BA	BB	BG	BR	BY	CA	CH	CN	CU	CZ	DE	DK	EE	ES	FI	GB
----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----

GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT UA UG UZ VN YU ZA ZW
AU 9942246 A 20000818 (200057)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000045177	A1	WO 1999-US12073	19990528
AU 9942246	A	AU 1999-42246	19990528

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9942246	A Based on	WO 200045177

PRIORITY APPLN. INFO: US 1999-117473 19990127